June 4, 2018 09:55 AM EDT
R&D

Vaxart re­ports PhII de­feat for a lega­cy an­tivi­ral from Avi­ra­gen — shares slide

Amber Tong

When Vaxart picked Avi­ra­gen Ther­a­peu­tics for the re­verse merg­er that got it on the Nas­daq, the South San Fran­cis­co biotech high­light­ed a Phase II treat­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times